Течение Хронического Миелолейкоза У Пациента С Панрезистентной Мутацией Т315і В Фазе Акселерации. Всегда Ли Необходима Аллогенная Трансплантация Костного Мозга При Мутации Т315і

CML patient with mutation T315I in accelerated phase, resistant to 2 lines of tyrosine-kinase inhibitors and Aurora-kinase inhibitor, is described. The progression of disease was not rapid. Other 5 patients with similar mutation are described with indolent course of the disease. Short review is presented about incidence of this mutation and its impact on the survival. Survival predominantly depends on the phase of the disease. Optimal treatment strategy is discussed.